Malignant brain tumors often fail to respond to promising new medication. Researchers in Heidelberg have discovered a mechanism and a tumor marker for the development of this resistance. A “death receptor” can possibly provide information as to how great the chances of success are for chemotherapy. At the same time, it offers a new approach for promising brain tumor therapy.

Duke University engineers have taken a first step toward a minimally invasive treatment of brain tumors by combining chemotherapy with heat administered from the end of a catheter.

Genetic aberrations in childhood brain tumors provide precise information on the course of the disease; Heidelberg researchers publish in the Journal of Clinical Oncology

A vaccine aimed at inducing immunity to the most common and deadly type of brain tumor may stave off recurrence and more than double survival in patients, according to a new study led by researchers in Duke’s Preston Robert Tisch Brain Tumor Center.

A new neuroimaging study at the Montreal Neurological Institute and Hospital at McGill University aims to ensure the highest quality of life for patients by assessing their cognitive skills before, during, and after brain tumour surgery. This is done by mapping the important functional brain areas surrounding the tumour in order to decrease the risks during surgery.

Unique human in vitro model (cell culture) research currently underway at the Peninsula Medical School in the South West of England is set to identify and develop therapies for the treatment of multiple tumours in the brain.

In the battle against malignant brain tumors, dual implantation of radioactive seeds and chemotherapy wafers following surgery showed promising results in a study led by specialists at the Neuroscience Institute at the University of Cincinnati (UC) and University Hospital.

A synthetic version of a molecule found in the egg cells of the Northern Leopard frog (Rana pipiens) could provide the world with the first drug treatment for brain tumours.

Chemotherapy temporarily hinders the body's immune response, creating a concern that it may interfere with the promising new cancer vaccines being used against brain tumors. But a new study led by researchers at the Preston Robert Tisch Brain Tumor Center at Duke University and The University of Texas M. D. Anderson Cancer Center has found that the opposite is true: chemotherapy may actually enhance the effectiveness of the vaccines.

Using metabolic or molecular imaging to measure brain tumor patients' response to treatment is a powerful predictor of survival, notes a first-of-its-kind study presented at the 54th Annual Meeting of SNM, the world's largest society for molecular imaging and nuclear medicine professionals.

A drug that targets the body's immune cells may be effective in treating malignant brain tumors, according to a new study led by researchers at Duke's Preston Robert Tisch Brain Tumor Center. In animal models, the drug re-engaged the body's cancer-damaged immune system.